Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure?
- PMID: 9651707
- DOI: 10.1093/eurheartj/19.6.842
Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure?
Abstract
A programme to detect and treat asymptomatic left ventricular dysfunction would seem to fulfil all five principles of screening. Indeed, such a programme would appear to be at least as firmly based as those already in existence for, for example, cervical and breast cancer. Further evaluation of the screening of high risk groups to detect asymptomatic left ventricular systolic dysfunction with the aim of giving treatment to prevent the development of heart failure is merited.
Similar articles
-
Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction.J Am Coll Cardiol. 1998 Sep;32(3):695-703. doi: 10.1016/s0735-1097(98)00297-6. J Am Coll Cardiol. 1998. PMID: 9741514 Clinical Trial.
-
Cost-effective strategies to screen for left ventricular systolic dysfunction in the community--a concept.Congest Heart Fail. 2005 Jul-Aug;11(4):194-8, 211. doi: 10.1111/j.1527-5299.2005.03494.x. Congest Heart Fail. 2005. PMID: 16106121 Review.
-
Evaluation of different strategies for identifying asymptomatic left ventricular dysfunction and pre-clinical (stage B) heart failure in the elderly. Results from 'PREDICTOR', a population based-study in central Italy.Eur J Heart Fail. 2013 Oct;15(10):1102-12. doi: 10.1093/eurjhf/hft098. Epub 2013 Jun 20. Eur J Heart Fail. 2013. PMID: 23787717
-
Angiotensin converting enzyme inhibition in asymptomatic left ventricular systolic dysfunction and early heart failure.Eur Heart J. 1995 Dec;16 Suppl N:59-64. doi: 10.1093/eurheartj/16.suppl_n.59. Eur Heart J. 1995. PMID: 8682063 Review.
-
The epidemiology of "asymptomatic" left ventricular systolic dysfunction: implications for screening.Ann Intern Med. 2003 Jun 3;138(11):907-16. doi: 10.7326/0003-4819-138-11-200306030-00012. Ann Intern Med. 2003. PMID: 12779301 Review.
Cited by
-
Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening.J Am Heart Assoc. 2013 Nov 7;2(6):e000399. doi: 10.1161/JAHA.113.000399. J Am Heart Assoc. 2013. PMID: 24200688 Free PMC article.
-
Blood signature of pre-heart failure: a microarrays study.PLoS One. 2011;6(6):e20414. doi: 10.1371/journal.pone.0020414. Epub 2011 Jun 24. PLoS One. 2011. PMID: 21731613 Free PMC article.
-
B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study.Circulation. 2003 Dec 16;108(24):2987-92. doi: 10.1161/01.CIR.0000103681.04726.9C. Epub 2003 Dec 8. Circulation. 2003. PMID: 14662720 Free PMC article.
-
Screening for left ventricular dysfunction in the community: role of hand held echocardiography and brain natriuretic peptides.Heart. 2003 Nov;89 Suppl 3(Suppl 3):iii24-8. doi: 10.1136/heart.89.suppl_3.iii24. Heart. 2003. PMID: 14594872 Free PMC article. Review. No abstract available.
-
Left ventricular dysfunction as a risk factor for cardiovascular and noncardiovascular hospitalizations in African Americans.Am Heart J. 2010 Sep;160(3):488-95. doi: 10.1016/j.ahj.2010.06.035. Am Heart J. 2010. PMID: 20826258 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical